Posted 5 months ago by Wales Gene Park
Brief Summary The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to < 18 years with advanced leukemias, lymphomas, and solid tumors.
Posted 5 months ago by Wales Gene Park
Brief Summary A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies, who are ineligible for or there are no available therapies known to confer a clinical benefit for their disease, or they have exhausted all such available options in each indication and therefore will be patients for whom a clinical trial is appropriate.
Posted 5 months ago by Wales Gene Park
Brief Summary The purpose of this study is to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers: Non-small Cell Lung Cancer (NSCLC) Triple Negative Breast Cancer (TNBC) Pancreatic Ductal Adenocarcinoma (PDAC) Colorectal Cancer Microsatellite Stable (MSS) Ovarian CancerRenal Cell Carcinoma (RCC) Metastatic Castration Resistant Prostate Cancer (mCRPC)
Posted 5 months ago by Wales Gene Park
Brief Summary The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to < 18 years with advanced leukemias, lymphomas, and solid tumors.